12 Best Multibagger Stocks to Buy in 2025

4. GeneDx Holdings Corp. (NASDAQ:WGS)

Number of Hedge Fund Holders: 32

Stock Price Return in the last twelve months: 909%

GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company that specializes in genetic testing and diagnostics for rare diseases and inherited conditions. It offers comprehensive genomic sequencing services, including whole genome sequencing, exome sequencing, and gene panel testing, to help identify genetic mutations and support personalized medicine. WGS primarily serves healthcare providers, clinicians, and research institutions, helping improve patient care through advanced genetic insights. The company focuses on expanding its diagnostic offerings to accelerate the understanding and treatment of genetic disorders.

GeneDx Holdings Corp. (NASDAQ:WGS) delivered exceptional Q4 results with revenues exceeding $95 million and gross margins expanding to 70%. The company’s exome and genome revenues grew significantly, showing a 101% YoY increase and 31% sequential growth, contributing $78.8 million in Q4. The company has set guidance for 2025 with expected revenues between $350 million and $360 million, projecting at least 30% growth in exome and genome volume and revenue. WGS has cemented its position as the market leader in exome and genome testing, with 8 out of 10 clinicians choosing their services for exome testing. The company’s data asset, comprising more than 750,000 exomes and genomes, provides a competitive advantage by enabling novel gene disease connections and ensuring high clinical utility.

In terms of operational improvements, GeneDx Holdings Corp. (NASDAQ:WGS) achieved an average reimbursement rate of approximately $3,500 for exome and genome after all denials in Q4, up from $3,100 last quarter and $2,500 in the same quarter last year. The company has launched its ultraRapid Whole Genome Sequencing product, which delivers results in as soon as 48 hours, demonstrating continued innovation in lab operations. Looking ahead, management plans to focus on expanding into the NICU market, developing new patient access channels, and strategically targeting opportunities outside the US. With a stock price return of 909% in the last twelve months, WGS is one of the best multibagger stocks to buy in 2025.